Table 1.
Summary of studies. HAI +/- SYS chemotherapy treatments for unresectable iCCA.
| Study | Number and Type of Patients | Treatment Regimen | PFS | OS |
|---|---|---|---|---|
| Cantore et al., 2005 [66] | 30 BTC •25 iCCA •5 gallbladder cancer |
3-week cycle HAI epirubicin 50 mg/m2, CIS 60 mg/m2 as bolus on Day 1 5-FU 200 mg/m2 per day by continuous infusion Day 1 to Day 14 |
7.1 months (C.I. 1.6–19.1) | 13.2 months |
| Jarnagin et al., 2009 [67] | 34 PLC •26 iCCA •8 HCC |
4-week cycle HAI: FUDR (0.16 mg/kg × 20/pump flow rate) and DEXA 25 mg on day 1 for 14-days of each cycle |
7.4 months | 29.5 months |
| Kemeny et al., 2011 [68] | 22 PLC •18 iCCA •4 HCC |
4-week cycle HAI: FUDR (0.16 mg/kg × 30/pump flow rate) and DEXA 25 mg on day 1 for 14-days of each cycle SYS: bevacizumab 5 mg/kg every other week. |
8.45 months (CI 5.53–11.05) | 31.1 months (CI 14.14–33.59) |
| Inaba et al., 2011 [69] | 13 iCCA | 4-week cycle HAI: GEM 1000 mg/m2 30-min infusion on days 1, 8, and 15 for 5 cycles |
- | 389 days (CI 158–620) |
| Ghiringhelli et al., 2013 [70] | 12 iCCA | Second-line treatment 2-week cycle HAI: GEM (1000 mg/m2 given over 30 min) followed by OX (100 mg/m2 given over 2 h) |
9.2 months (CI 2.1–29.4) | 20.3 months (CI 13.2–49.7) |
| Massani et al., 2015 [38] | 11 iCCA | 2-week cycle HAI: Day 1: 100 mg/mq of OX Day 2: 5 FU 7 mg/kg at 2 mL/h in CI for 48 h |
- | 17.6 months |
| Konstantinidis et al., 2016 [71]. | 104 iCCA •78 HAI/SYS •26 SYS |
4-week cycle HAI: FUDR (0.16 mg/kg × 20/pump flow rate) and DEXA 25 mg on day 1 for 14-days of each cycle SYS: mostly GEM based |
HAI/SYS 12 months SYS 7 months |
HAI/SYS 30.8 months SYS 18.4 months |
| Higaki et al., 2018 [72] | 12 iCCA | 42-day cycle HAI: CIS 65 mg/m2 2 mL/min on Day 1 SYS: S-1 60 mg/m2 per day 1–28. |
- | 10.1 months (CI 3.6–23.2) |
| Cercek A, et al., 2019 [33] | 38 iCCA | 4-week cycle HAI: FUDR (0.12 mg/kg × 30/pump flow rate) and DEXA 30 mg/pump on day 1 for 14-days of each cycle SYS: GEM (800 mg/m2) with OX (85 mg/m2) on Day 1 or 15, every 2 weeks |
11.8 months (1-sided 90% CI, 11.1) | 25.0 months (95% CI, 20.6-not reached) |
Table legend: PFS, progression-free survival; OS, overall survival; BTC, biliary tract cancer; PLC, primary liver carcinoma; iCCA, intrahepatic cholangiocarcinoma; HCC, hepatocarcinoma; CI, confidence interval; HAI, hepatic arterial infusion; SYS, systemic; FUDR, floxuridine; GEM, gemcitabine; CIS, cisplatin; OX, oxaliplatin; DEXA, dexamethasone; 5-FU, 5-fluorouracil.